{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:42:48Z","timestamp":1768408968747,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-025-02665-0","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T03:24:28Z","timestamp":1749957868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk-adapted intensification therapy in high-risk prostate cancer: how relevant is the role of radiation dose"],"prefix":"10.1186","volume":"20","author":[{"given":"A.","family":"Zapatero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Roch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mart\u00edn de Vidales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Montes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cruz Conde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fern\u00e1ndez-Banda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Zaragoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Carroceda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Garc\u00eda Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,15]]},"reference":[{"issue":"2","key":"2665_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86(2):148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol."},{"key":"2665_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.radonc.2013.09.026","volume":"110","author":"WD Heemsbergen","year":"2014","unstructured":"Heemsbergen WD, Al-Mamgani A, Slot A, Dielwart MF, Lebesque JV. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110:104\u20139.","journal-title":"Radiother Oncol"},{"issue":"4","key":"2665_CR3","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","volume":"80","author":"V Beckendorf","year":"2011","unstructured":"Beckendorf V, Guerif S, Le Pris\u00e9 E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056\u201363.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2665_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","volume":"15","author":"DP Dearnaley","year":"2014","unstructured":"Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15(4):464\u201373.","journal-title":"Lancet Oncol"},{"key":"2665_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"WJ Morris","year":"2017","unstructured":"Morris WJ, Tyldesley S, Rodda S, et al. Androgen suppression combined with elective nodal and dose escalated radiationtherapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98:275\u201385.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2665_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.02.045","volume":"104","author":"D Pasalic","year":"2019","unstructured":"Pasalic D, Kuban DA, Allen PK, et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. Int J Radiat Oncol Biol Phys. 2019;104:790\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2665_CR7","doi-asserted-by":"publisher","first-page":"LBA259","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA259","volume":"42","author":"C Hennequin","year":"2024","unstructured":"Hennequin C, Sargos P, Roca L, et al. Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial. J Clin Oncol. 2024;42(4):LBA259\u2013LBA259. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.LBA259.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2665_CR8","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s12094-017-1655-9","volume":"19","author":"A Zapatero","year":"2017","unstructured":"Zapatero A, Roch M, B\u00fcchser D, et al. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer. Clin Transl Oncol. 2017;19(9):1161\u20137. https:\/\/doi.org\/10.1007\/s12094-017-1655-9. (Epub 2017 Apr 3 PMID: 28374321).","journal-title":"Clin Transl Oncol"},{"key":"2665_CR9","unstructured":"Gray B (2024). _cmprsk: Subdistribution Analysis of Competing Risks_. R package version 2.2\u201312, <https:\/\/CRAN.R-project.org\/package=cmprsk>."},{"issue":"5","key":"2665_CR10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(22)00190-5","volume":"23","author":"A Zapatero","year":"2022","unstructured":"Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01\/05): 10-year results of a phase 3 randomised, controlled trial. Lancet Oncol. 2022;23(5):671\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(22)00190-5. (Epub 2022 Apr 12 PMID: 35427469).","journal-title":"Lancet Oncol"},{"key":"2665_CR11","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.1200\/JCO.2005.09.662","volume":"23","author":"A Zapatero","year":"2005","unstructured":"Zapatero A, Valcarcel F, Calvo FA, et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol. 2005;23:6561\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2665_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ijrobp.2019.11.415","volume":"106","author":"D Joseph","year":"2020","unstructured":"Joseph D, Denham JW, Steigler A, et al. Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-Year data from the TROG 0304 RADAR trial. Int J Radiat Oncol Biol Phys. 2020;106(4):693\u2013702. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.11.415. (PMID: 32092343).","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2665_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110024","volume":"190","author":"A Gomez-Iturriaga","year":"2024","unstructured":"Gomez-Iturriaga A, Zaragoza L, Valverde I, et al. Prospective study of HDR brachytherapy (BT), external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT): 10-years experience of an MRI-guided approach. Radiother Oncol. 2024;190: 110024. https:\/\/doi.org\/10.1016\/j.radonc.2023.110024. (Epub 2023 Nov 22 PMID: 37995851).","journal-title":"Radiother Oncol"},{"key":"2665_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.radonc.2018.10.013","volume":"132","author":"TB Wedde","year":"2019","unstructured":"Wedde TB, Sm\u00e5stuen MC, Brabrand S, et al. Ten-year survival after high-dose-rate brachytherapy combined with external beam radiation therapy in high-risk prostate cancer: a comparison with the Norwegian SPCG-7 cohort. Radiother Oncol. 2019;132:211\u20137. https:\/\/doi.org\/10.1016\/j.radonc.2018.10.013. (Epub 2018 Oct 30 PMID: 30389241).","journal-title":"Radiother Oncol"},{"key":"2665_CR15","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","volume":"19","author":"M Roach","year":"2018","unstructured":"Roach M, Moughan J, Lawton CAF, et al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localized prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial [published correction appears in Lancet Oncol 2018;19:e581]. Lancet Oncol. 2018;19:1504\u201315.","journal-title":"Lancet Oncol"},{"key":"2665_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ijrobp.2016.06.2455","volume":"96","author":"P Pommier","year":"2016","unstructured":"Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys. 2016;96:759\u201369.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2665_CR17","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1200\/JCO.20.03282","volume":"39","author":"V Murthy","year":"2021","unstructured":"Murthy V, Maitre P, Kannan S, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol. 2021;39:1234\u201342.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2665_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer LGW, Groen VH, Pos FJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol. 2021;39(7):787\u201396. https:\/\/doi.org\/10.1200\/JCO.20.02873. (Epub 2021 Jan 20 PMID: 33471548).","journal-title":"J Clin Oncol"},{"issue":"2","key":"2665_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.euo.2022.10.001","volume":"6","author":"DMC Poon","year":"2023","unstructured":"Poon DMC, Yuan J, Yang B, et al. Magnetic resonance imaging\u2013guided focal boost to intraprostatic lesions using external beam radiotherapy for localized prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2023;6(2):116\u201327. https:\/\/doi.org\/10.1016\/j.euo.2022.10.001.","journal-title":"Eur Urol Oncol"},{"issue":"10196","key":"2665_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6. (Epub 2019 Jun 18 PMID: 31227373).","journal-title":"Lancet"},{"issue":"3","key":"2665_CR21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ijrobp.2021.01.016","volume":"110","author":"R van Dams","year":"2024","unstructured":"van Dams R, Jiang NY, Fuller DB, et al. Stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (SHARP) consortium: analysis of 344 prospectively treated patients. Int J Radiat Oncol Biol Phys. 2024;110(3):731\u20137.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2665_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijrobp.2024.03.009","volume":"120","author":"B Yasar","year":"2024","unstructured":"Yasar B, Suh YE, Chapman E, et al. Simultaneous focal boost with stereotactic radiation therapy for localized intermediate- to high-risk prostate cancer: primary outcomes of the SPARC Phase 2 trial. Int J Radiat Oncol Biol Phys. 2024;120(1):49\u201358. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.03.009. (Epub 2024 Mar 16 PMID: 38499253).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2665_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110568","volume":"201","author":"C Draulans","year":"2024","unstructured":"Draulans C, Haustermans K, Pos FJ, et al. Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial. Radiother Oncol. 2024;201: 110568. https:\/\/doi.org\/10.1016\/j.radonc.2024.110568. (Epub 2024 Oct 2 PMID: 39362607).","journal-title":"Radiother Oncol"},{"key":"2665_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijrobp.2024.12.018","volume":"12","author":"V Murthy","year":"2025","unstructured":"Murthy V, Mallick I, Maitre P, et al. Pelvic regional control with 25 Gy in 5 fractions in stereotactic radiation therapy for high-risk prostate cancer: pooled prospective outcomes from the SHARP consortium. Int J Radiat Oncol Biol Phys. 2025;12:93\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.12.018. (Epub ahead of print. PMID: 39755216).","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"12","key":"2665_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.863848","volume":"13","author":"W Liu","year":"2022","unstructured":"Liu W, Loblaw A, Laidley D, et al. Imaging biomarkers in prostate stereotactic body radiotherapy: a review and clinical trial protocol. Front Oncol. 2022;13(12): 863848. https:\/\/doi.org\/10.3389\/fonc.2022.863848. (PMID: 35494042; PMCID: PMC9043802).","journal-title":"Front Oncol"},{"issue":"12","key":"2665_CR26","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1016\/S1470-2045(24)00635-1","volume":"25","author":"MJ Karpinski","year":"2024","unstructured":"Karpinski MJ, H\u00fcsing J, Claassen K, et al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol. 2024;25(12):e626. https:\/\/doi.org\/10.1016\/S1470-2045(24)00635-1. (PMID: 39089299).","journal-title":"Lancet Oncol."},{"issue":"2","key":"2665_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.eururo.2024.11.025","volume":"87","author":"J Stranne","year":"2025","unstructured":"Stranne J, Henry A, Oprea-Lager DE. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Prostate Cancer Guidelines Panel. Use of prostate-specific membrane antigen positron emission tomography\/computed tomography for nodal staging in prostate cancer and tailoring of treatment: a continuing conundrum. Eur Urol. 2025;87(2):108\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.025. (Epub 2024 Dec 18. PMID: 39701872).","journal-title":"Eur Urol."},{"issue":"2","key":"2665_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.euo.2024.09.015","volume":"8","author":"EJE van Altena","year":"2025","unstructured":"van Altena EJE, Jansen BHE, Korbee ML, et al. Prostate-specific membrane antigen positron emission tomography before reaching the phoenix criteria for biochemical recurrence of prostate cancer after radiotherapy: earlier detection of recurrences. Eur Urol Oncol. 2025;8(2):417\u201324. https:\/\/doi.org\/10.1016\/j.euo.2024.09.015. (Epub ahead of print. PMID: 39414419).","journal-title":"Eur Urol Oncol"},{"issue":"13","key":"2665_CR29","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1007\/s00259-023-06382-2","volume":"50","author":"J Kendrick","year":"2023","unstructured":"Kendrick J, Francis RJ, Hassan GM, et al. Prognostic utility of RECIP 1.0with manual and AI-based segmentations in biochemically recurrent prostate cancer from [68Ga]Ga-PSMA-11 PET images. Eur J Nucl Med Mol Imaging. 2023;50(13):4077\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02665-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02665-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02665-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T03:24:29Z","timestamp":1749957869000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02665-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,15]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2665"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02665-0","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,15]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This is retrospective analysis of a prospective cohort, not a clinical trial. But, all patients signed an ICF prior to radiation therapy as clinical practice in all cases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The clinical research of the present manuscripts comply with international and national standards for such work (such as the Declaration of Helsinki )","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}